Integral Diagnostics Ltd
ASX:IDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Integral Diagnostics Ltd
ASX:IDX
|
AU |
|
Rhythm Biosciences Ltd
ASX:RHY
|
AU |
|
H
|
Healius Ltd
ASX:HLS
|
AU |
|
Australian Clinical Labs Ltd
ASX:ACL
|
AU |
Integral Diagnostics Ltd
Integral Diagnostics Ltd. engages in the provision of diagnostic imaging services to general practitioners, medical specialists, and allied professionals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-10-21. The firm is principally engaged in providing medical imaging services to patients and their referrers across Australia and New Zealand. The firm offers its services through its three brands in Australian states, which include Lake Imaging in Victoria, South Coast Radiology and Imaging Queensland in Queensland and Apex Radiology in Western Australia. IDX also operates in New Zealand through the Ascot Radiology, SRG Radiology and Trinity MRI brands. The firm has approximately 72 radiology clinics, including 26 comprehensive sites. IDX offers its services through its subsidiaries.
Integral Diagnostics Ltd. engages in the provision of diagnostic imaging services to general practitioners, medical specialists, and allied professionals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-10-21. The firm is principally engaged in providing medical imaging services to patients and their referrers across Australia and New Zealand. The firm offers its services through its three brands in Australian states, which include Lake Imaging in Victoria, South Coast Radiology and Imaging Queensland in Queensland and Apex Radiology in Western Australia. IDX also operates in New Zealand through the Ascot Radiology, SRG Radiology and Trinity MRI brands. The firm has approximately 72 radiology clinics, including 26 comprehensive sites. IDX offers its services through its subsidiaries.
Revenue Surge: Integral Diagnostics reported first half FY26 revenue of $393.5 million, up 55.6%, driven largely by the Capitol merger.
Margin Expansion: Operating EBITDA margin increased by 230 basis points to 20.6%, with improvement seen across all earnings lines.
EPS & Dividend Growth: Operating diluted EPS grew 66.2% to $0.059 per share and interim dividend rose 32% to $0.033 per share.
Synergy Outperformance: Annual synergies from the Capitol merger exceeded expectations at over $14 million, well above the original $10 million estimate.
Leverage Down: Net debt-to-EBITDA ratio reduced to 2.5x from 2.8x, with strong liquidity and more than half of debt now hedged at favorable rates.
Guidance Maintained: FY26 operating EBITDA margin expected to be around 21%, with continued revenue growth anticipated.
CapEx & Growth: $24.9 million invested in CapEx during the half; three new greenfield sites to open in Q4, but meaningful contributions expected in FY27.
Teleradiology & AI: Teleradiology now at 15% penetration and expected to rise, offering 4–5% margin benefit; around 10% of scans processed with AI.
